VIP (Vasoactive Intestinal Peptide): Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 14 sources cited
Overview
Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide with broad physiological functions including vasodilation, immunomodulation, neuroprotection, and regulation of circadian rhythms. It is found throughout the central and peripheral nervous systems, the gastrointestinal tract, and the immune system. VIP has gained attention for its potential therapeutic applications in chronic inflammatory conditions, mast cell activation syndrome (MCAS), mold illness (CIRS), and neurodegenerative diseases.
Mechanism of Action
VIP signals through two G-protein coupled receptors: VPAC1 (widely expressed in the CNS, liver, lungs, and immune cells) and VPAC2 (predominant in the CNS, pancreas, and smooth muscle). Both receptors activate adenylyl cyclase via Gsα, increasing intracellular cAMP levels and activating protein kinase A (PKA). This triggers diverse tissue-specific effects. In blood vessels, VIP is one of the most potent endogenous vasodilators, relaxing smooth muscle via cAMP-mediated inhibition of myosin light chain kinase. In the immune system, VIP is a potent anti-inflammatory mediator — it suppresses pro-inflammatory cytokine production (TNF-α, IL-6, IL-12), inhibits NF-κB activation, promotes regulatory T-cell differentiation, and shifts macrophages from M1 (inflammatory) to M2 (resolving) phenotype. In the nervous system, VIP acts as a neuroprotective agent — it enhances neuronal survival, promotes neurite outgrowth, and modulates glutamate excitotoxicity. VIP also regulates circadian rhythms through its action on the suprachiasmatic nucleus (SCN) master clock. In CIRS (chronic inflammatory response syndrome), one open-label study of 20 patients with no control group reported that intranasal VIP corrected inflammatory markers and exercise-induced pulmonary artery pressure.
VIP (Vasoactive Intestinal Peptide) Benefits: What the Research Shows
- Delgado et al. (1999, Journal of Immunology) demonstrated VIP's potent anti-inflammatory effects, showing it protected mice from lethal endotoxemia by reducing TNF-α and IL-6
- Shoemaker et al. (2013) reported, in an open-label study of 20 CIRS patients with no control group, improvement in exercise-induced pulmonary artery pressure and inflammatory markers (TGF-β1, MMP-9, C4a) with intranasal VIP
- Gonzalez-Rey et al. (2007, Annals of the Rheumatic Diseases) reviewed VIP's role as an anti-inflammatory neuropeptide with therapeutic potential in autoimmune diseases
- VIP has shown neuroprotective effects in cell and animal models of beta-amyloid toxicity (an Alzheimer's disease model) and brain trauma, by reducing microglial inflammation
- Studies demonstrate VIP promotes regulatory T-cell differentiation and immune tolerance
- Research in mice shows VIP signaling in the SCN keeps clock neurons synchronized; mice lacking VIP lose normal circadian rhythms, and a VIP receptor agonist restored rhythmicity in their SCN neurons
VIP (Vasoactive Intestinal Peptide) Dosage
- CIRS/mold illness protocol (Shoemaker): 50 mcg intranasally 4 times daily, titrating up based on response
- Some protocols start at 25 mcg intranasally 2–3 times daily and titrate to 50 mcg 4x daily
- Research doses vary: 1–10 mcg/kg IV for acute vasodilation studies
- Intranasal is the preferred route for CNS and systemic immune effects
- Cycle: used continuously for chronic conditions (CIRS, MCAS) until inflammatory markers normalize
- Must pass VCS (visual contrast sensitivity) test and have MARCoNS (nasal staph) treated before starting VIP per Shoemaker protocol
- Some protocols use subcutaneous injection at 50–100 mcg daily as an alternative to intranasal
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
VIP (Vasoactive Intestinal Peptide) Side Effects & Safety
Known Side Effects
- Nasal irritation and rhinorrhea with intranasal administration
- Transient hypotension and facial flushing (due to potent vasodilatory effects)
- Diarrhea at higher doses (VIP stimulates intestinal secretion; IV infusion caused watery diarrhea in healthy volunteers and in about a third of patients in a COVID-19 trial)
- Headache related to vasodilation
- Tachycardia as a reflex response to vasodilation
- Rare: water retention and electrolyte disturbances at high systemic doses
Safety Profile
VIP is an endogenous peptide with natural biocompatibility. At intranasal doses used in CIRS protocols, systemic side effects are generally mild. The primary concern is hypotension in susceptible individuals — patients with low baseline blood pressure should start at lower doses. VIP should be used cautiously in patients with active malignancy, as it has both pro-angiogenic and immunosuppressive properties that could theoretically support tumor growth. In the Shoemaker CIRS protocol, VIP is used only after other inflammatory triggers have been addressed (mold avoidance, binders, MARCoNS treatment), as premature VIP use may be less effective or mask ongoing exposure. Not FDA-approved for any indication. Drug interactions include potential additive hypotension with antihypertensives. Not studied in pregnancy.
What to Expect
Week 1–2: Mild vasodilatory effects may be noticeable (facial warmth, slight blood pressure drop). Nasal irritation is common with intranasal use. Some CIRS patients report initial 'herx-like' reactions as inflammatory pathways are modulated. Week 2–4: Anti-inflammatory effects become apparent. CIRS patients may notice improved energy, reduced brain fog, and improved respiratory symptoms. Inflammatory markers (if monitored) begin trending downward. Week 4–8: Sustained improvement in CIRS symptoms. In the one uncontrolled CIRS study, exercise-induced pulmonary artery pressure returned to normal. Sleep quality and circadian rhythm regulation may improve. Week 8+: Full therapeutic effects in chronic conditions. In that study, CIRS patients' lab markers (TGF-β1, C4a, MMP-9) and quality of life improved. Ongoing use may be needed for sustained benefit.
Common Stacks
BPC-157
BPC-157 modulates nitric oxide systems and supports tissue repair, complementing VIP's vasodilatory and anti-inflammatory effects in CIRS and chronic inflammatory conditions
KPV
KPV (alpha-MSH fragment) provides potent anti-inflammatory effects through melanocortin receptors, complementing VIP's VPAC-mediated immunomodulation for comprehensive inflammation control
Thymosin Alpha-1
Tα1 enhances adaptive immune function while VIP modulates innate inflammation — together they balance immune activation and resolution
Storage & Handling
Store lyophilized VIP at -20°C for long-term storage (2+ years). At 2–8°C, stable for up to 6 months. Reconstitute with bacteriostatic water for injection; intranasal preparations require specific compounding. Reconstituted solution: store at 2–8°C and use within 14–21 days. Protect from light. The peptide is sensitive to enzymatic degradation — avoid contamination. Intranasal spray bottles: store at 2–8°C, use within 30 days.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- Harmar AJ, Fahrenkrug J, Gozes I, et al. Pharmacology and functions of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide: IUPHAR review 1. Br J Pharmacol. 2012.
- Brown SM, Barkauskas CE, Grund B, et al. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial. Lancet Respir Med. 2023.
- Youssef JG, Lavin P, Schoenfeld DA, et al. The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial. Crit Care Med. 2022.
- Prasse A, Zissel G, Lützen N, et al. Inhaled vasoactive intestinal peptide exerts immunoregulatory effects in sarcoidosis. Am J Respir Crit Care Med. 2010.
- Shoemaker RC, House D, Ryan JC. Vasoactive intestinal polypeptide (VIP) corrects chronic inflammatory response syndrome (CIRS) acquired following exposure to water-damaged buildings. Health. 2013.
- Delgado M, Martinez C, Pozo D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activation polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-alpha and IL-6. J Immunol. 1999.
- Gonzalez-Rey E, Anderson P, Delgado M. Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy. Ann Rheum Dis. 2007.
- Delgado M, Chorny A, Gonzalez-Rey E, et al. Vasoactive intestinal peptide generates CD4+CD25+ regulatory T cells in vivo. J Leukoc Biol. 2005.
- Aton SJ, Colwell CS, Harmar AJ, et al. Vasoactive intestinal polypeptide mediates circadian rhythmicity and synchrony in mammalian clock neurons. Nat Neurosci. 2005.
- Delgado M, Ganea D. Vasoactive intestinal peptide prevents activated microglia-induced neurodegeneration under inflammatory conditions: potential therapeutic role in brain trauma. FASEB J. 2003.
- Delgado M, Varela N, Gonzalez-Rey E. Vasoactive intestinal peptide protects against beta-amyloid-induced neurodegeneration by inhibiting microglia activation at multiple levels. Glia. 2008.
- Frase LL, Gaffney FA, Lane LD, et al. Cardiovascular effects of vasoactive intestinal peptide in healthy subjects. Am J Cardiol. 1987.
- Kane MG, O'Dorisio TM, Krejs GJ. Production of secretory diarrhea by intravenous infusion of vasoactive intestinal polypeptide. N Engl J Med. 1983.
- Collado B, Carmena MJ, Clemente C, et al. Vasoactive intestinal peptide enhances growth and angiogenesis of human experimental prostate cancer in a xenograft model. Peptides. 2007.
Related Peptides
Track VIP (Vasoactive Intestinal Peptide) in Your Protocol
Log your VIP (Vasoactive Intestinal Peptide) doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free